Tender Details

Country:
Summary: Amyotrophic Lateral Sclerosis (Als) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
UST Ref No: 107811296
Deadline: 24 Jan 2025
Financier:
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.: RFA-NS-25-024
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
The National Institute Of Neurological Disorders And Stroke (Ninds) And The Office Of The Director, National Institutes Of Health (Od), Intend To Promote A New Initiative By Publishing A Funding Opportunity Announcement (Foa) To Solicit Applications For The Conduct Of Scientific Research Utilizing Data From Expanded Access (Ea) To Investigational Drugs Or Biological Products. These Applications Will Target Intermediate Size Populations Of Patients Living With Amyotrophic Lateral Sclerosis (Als) Who Are Not Otherwise Eligible For Clinical Trials For The Diagnosis, Mitigation, Treatment, Or Cure Of Als ("Intermediate Ea Protocol For Als"). Providing The Investigational Drug Or Biological Product Under An Intermediate Ea Protocol For Als Must Not Interfere With The Initiation, Conduct, Or Completion Of Clinical Investigations That Could Support Marketing Approval, Or Otherwise Compromise The Potential Development Of Medical Products For The Diagnosis, Mitigation, Treatment, Or Cure Of Als. Eligible Applicants Are Clinical Trial Sites That Participate In A Phase 3 Clinical Trial Supported By A United States (U.S.) Small Business Concern (As Defined In Section 3(A) Of The Small Business Act (15 U.S. C. 623(A)) That Is Also The U.S. Food And Drug Administration (Fda) Designated Sponsor Of A Drug Or Biological Product For Als That Is The Subject Of An Investigational New Drug Application (Ind). This Notice Is Being Provided To Allow Potential Applicants Sufficient Time To Develop Me...
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Amyotrophic Lateral Sclerosis (Als) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) - USA Tender

The NATIONAL INSTITUTES OF HEALTH, a Government sector organization in , has announced a new tender for Amyotrophic Lateral Sclerosis (Als) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required). This tender is published on USARFP under UST Ref No: 107811296 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-01-24.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.